More stories
Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves...
On Wednesday, Bloomberg became the first to publicly report on a rumour that has been working its way around the field in the past...
Mareesa Stertz & Tania Abdul – Sphinx Gate: Know Thyself at Burning Man
In this episode, Joe Moore is joined by Mareesa Stertz and Tania Abdul, the visionaries behind Sphinx Gate, one of Burning Man 2025’s most...
Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health
Germany’s decision to permit psilocybin therapy for patients with treatment-resistant depression—under a compassionate use policy—marks a pivotal shift in European drug policy. It may...
Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s...
In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape...
Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices
In this episode of Psychedelics Today, Joe Moore sits down with Chad Charles — educator, mentor, and practitioner specializing in 5-MeO-DMT therapy. Chad shares...
Germany Establishes EU’s First Psilocybin Compassionate Access Program
Germany has become the first country in the European Union to allow legal access to a psychedelic, under certain conditions, prior to regulatory approval.Through...
Chad Charles – Integrating 5-MeO-DMT: Therapy, Harm Reduction, and Best Practices
In this episode of Psychedelics Today, Joe Moore sits down with Chad Charles — educator, mentor, and practitioner specializing in 5-MeO-DMT therapy. Chad shares...
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons...
In her first Dispatch, Dr. Alaina Jaster covered the inaugural Neurobiology of Psychedelics Gordon Research Conference’s Keynote Sessio,n plus the first day of the...
William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine
https://www.youtube.com/watch?v=_zvMirUduxs
Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher...
On Wednesday, GH Research announced that FDA is retaining a clinical hold on its Investigational New Drug (IND) application to commence a trial of...
June 2025 Psychedelic Patent Update
The Psychedelic Patent Update provides headline figures and data regarding published psychedelic patent applications and grants. We added 17 PCTs and 34 U.S. patent...
Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s...
In this episode of Psychedelics Today, Joe Moore sits down with Alan Davis, Associate Professor at Ohio State University, to explore the evolving landscape...
